Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,592,000 | 698,000 | 1,041,000 | -82,000 | 4,700,000 |
| Depreciation Amortization | 1,254,000 | 1,268,000 | 1,463,000 | 1,656,000 | 1,116,000 |
| Income taxes - deferred | -1,000 | -63,000 | -124,000 | -82,000 | -4,301,000 |
| Accounts receivable | -238,000 | -220,000 | -279,000 | 335,000 | -130,000 |
| Other Working Capital | -770,000 | -1,005,000 | -351,000 | -23,000 | -296,000 |
| Other Operating Activity | 666,000 | 848,000 | 120,000 | -296,000 | 747,000 |
| Operating Cash Flow | $2,503,000 | $1,526,000 | $1,870,000 | $1,508,000 | $1,836,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -707,000 | -576,000 | -540,000 | -364,000 | -454,000 |
| Net Acquisitions | -1,811,000 | -1,537,000 | -1,432,000 | -134,000 | -4,292,000 |
| Purchase Of Investment | -89,000 | -24,000 | 279,000 | N/A | -149,000 |
| Other Investing Activity | 33,000 | 126,000 | 96,000 | 87,000 | -146,000 |
| Investing Cash Flow | $-2,574,000 | $-2,011,000 | $-1,597,000 | $-411,000 | $-5,041,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -4,000 | -1,000 | N/A | 3,447,000 | 125,000 |
| Debt Issued | 0 | 3,270,000 | 0 | 1,683,000 | 7,229,000 |
| Debt Repayment | N/A | -3,184,000 | N/A | -1,260,000 | -3,560,000 |
| Common Stock Issued | 182,000 | 136,000 | 110,000 | 1,086,000 | 123,000 |
| Common Stock Repurchased | N/A | N/A | N/A | -535,000 | N/A |
| Dividend Paid | -28,000 | -55,000 | -55,000 | -28,000 | N/A |
| Other Financing Activity | -145,000 | -714,000 | -150,000 | -4,100,000 | -944,000 |
| Financing Cash Flow | $5,000 | $-548,000 | $-95,000 | $293,000 | $2,973,000 |
| Exchange Rate Effect | -4,000 | -9,000 | -6,000 | -2,000 | 10,000 |
| Beginning Cash Position | 1,126,000 | 2,168,000 | 1,995,000 | 607,000 | 829,000 |
| End Cash Position | 1,055,000 | 1,126,000 | 2,168,000 | 1,995,000 | 607,000 |
| Net Cash Flow | $-70,000 | $-1,042,000 | $173,000 | $1,388,000 | $-222,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,503,000 | 1,526,000 | 1,870,000 | 1,508,000 | 1,836,000 |
| Capital Expenditure | -711,000 | -588,000 | -554,000 | -376,000 | -461,000 |
| Free Cash Flow | 1,792,000 | 938,000 | 1,316,000 | 1,132,000 | 1,375,000 |